CerSci Therapeutics

CerSci Therapeutics was a clinical-stage biotechnology company founded in Dallas, Texas in 2015 focused on developing next-generation non-opioid small molecule therapeutics targeting reactive oxygen species pathways for the treatment and prevention of acute postoperative and chronic neuropathic pain. Its lead program ACP‑044 advanced through Phase I trials showing favorable safety/tolerability data with plans for further development under new ownership by Acadia Pharmaceuticals following its August 2020 acquisition ($52.5M upfront). The company's approach centered on a first-in-class RSDAx mechanism designed to interrupt multiple neuronal sensitization pathways without opioid receptor engagement or addiction risk—a significant differentiator amid the ongoing opioid epidemic.